Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis - PubMed (original) (raw)
Review
. 2011 Mar 16;305(11):1119-27.
doi: 10.1001/jama.2011.308.
Affiliations
- PMID: 21406649
- DOI: 10.1001/jama.2011.308
Review
Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis
Suetonia C Palmer et al. JAMA. 2011.
Abstract
Context: Clinical practice guidelines on the management of mineral and bone disorders due to chronic kidney disease recommend specific treatment target levels for serum phosphorus, parathyroid hormone, and calcium.
Objective: To assess the quality of evidence for the association between levels of serum phosphorus, parathyroid hormone, and calcium and risks of death, cardiovascular mortality, and nonfatal cardiovascular events in individuals with chronic kidney disease.
Data sources: The databases of MEDLINE (1948 to December 2010) and EMBASE (1947 to December 2010) were searched without language restriction. Hand searches also were conducted of the reference lists of primary studies, review articles, and clinical guidelines along with full-text review of any citation that appeared relevant.
Study selection: Of 8380 citations identified in the original search, 47 cohort studies (N = 327,644 patients) met the inclusion criteria.
Data extraction: The characteristics of study design, participants, exposures, and covariates together with the outcomes of all-cause mortality, cardiovascular mortality, and nonfatal cardiovascular events at different levels of serum phosphorus, parathyroid hormone, and calcium were analyzed within studies. Data were summarized across studies (when possible) using random-effects meta-regression.
Data synthesis: The risk of death increased 18% for every 1-mg/dL increase in serum phosphorus (relative risk [RR], 1.18 [95% confidence interval {CI}, 1.12-1.25]). There was no significant association between all-cause mortality and serum level of parathyroid hormone (RR per 100-pg/mL increase, 1.01 [95% CI, 1.00-1.02]) or serum level of calcium (RR per 1-mg/dL increase, 1.08 [95% CI, 1.00-1.16]). Data for the association between serum level of phosphorus, parathyroid hormone, and calcium and cardiovascular death were each available in only 1 adequately adjusted cohort study. Lack of adjustment for confounding variables was not a major limitation of the available studies.
Conclusions: The evidentiary basis for a strong, consistent, and independent association between serum levels of calcium and parathyroid hormone and the risk of death and cardiovascular events in chronic kidney disease is poor. There appears to be an association between higher serum levels of phosphorus and mortality in this population.
Comment in
- Mineral metabolism disorders in chronic kidney disease.
Kestenbaum B. Kestenbaum B. JAMA. 2011 Mar 16;305(11):1138-9. doi: 10.1001/jama.2011.339. JAMA. 2011. PMID: 21406655 No abstract available. - Mortality in chronic kidney disease and mineral metabolism.
Floege J, Kronenberg F, Froissart M. Floege J, et al. JAMA. 2011 Jul 13;306(2):159; author reply 159-60. doi: 10.1001/jama.2011.948. JAMA. 2011. PMID: 21750291 No abstract available. - What should a guideline panel do when evidence is inconclusive? The case of treatments for CKD-mineral and bone disorder (CKD-MBD).
Uhlig K. Uhlig K. Am J Kidney Dis. 2011 Dec;58(6):872-5. doi: 10.1053/j.ajkd.2011.08.001. Epub 2011 Sep 3. Am J Kidney Dis. 2011. PMID: 21890254 No abstract available.
Similar articles
- Calcium, phosphorus, parathyroid hormone, and cardiovascular disease in hemodialysis patients: the USRDS waves 1, 3, and 4 study.
Slinin Y, Foley RN, Collins AJ. Slinin Y, et al. J Am Soc Nephrol. 2005 Jun;16(6):1788-93. doi: 10.1681/ASN.2004040275. Epub 2005 Apr 6. J Am Soc Nephrol. 2005. PMID: 15814832 - Association of Drug Effects on Serum Parathyroid Hormone, Phosphorus, and Calcium Levels With Mortality in CKD: A Meta-analysis.
Palmer SC, Teixeira-Pinto A, Saglimbene V, Craig JC, Macaskill P, Tonelli M, de Berardis G, Ruospo M, Strippoli GF. Palmer SC, et al. Am J Kidney Dis. 2015 Dec;66(6):962-71. doi: 10.1053/j.ajkd.2015.03.036. Epub 2015 May 21. Am J Kidney Dis. 2015. PMID: 26003472 Review. - Mineral metabolism disorders in chronic kidney disease.
Kestenbaum B. Kestenbaum B. JAMA. 2011 Mar 16;305(11):1138-9. doi: 10.1001/jama.2011.339. JAMA. 2011. PMID: 21406655 No abstract available. - Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study.
Naves-Díaz M, Passlick-Deetjen J, Guinsburg A, Marelli C, Fernández-Martín JL, Rodríguez-Puyol D, Cannata-Andía JB. Naves-Díaz M, et al. Nephrol Dial Transplant. 2011 Jun;26(6):1938-47. doi: 10.1093/ndt/gfq304. Epub 2010 May 31. Nephrol Dial Transplant. 2011. PMID: 20513773 - Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
Navaneethan SD, Palmer SC, Craig JC, Elder GJ, Strippoli GF. Navaneethan SD, et al. Am J Kidney Dis. 2009 Oct;54(4):619-37. doi: 10.1053/j.ajkd.2009.06.004. Epub 2009 Aug 18. Am J Kidney Dis. 2009. PMID: 19692157 Review.
Cited by
- Relationship of serum calcium concentration with chronic kidney disease and mortality in type 2 diabetes mellitus patients: evidence from the NHANES 1999-2018.
Qiu M, Chen Y, Ke B, Fang X, Xu C, Hua J. Qiu M, et al. Int Urol Nephrol. 2024 Nov 15. doi: 10.1007/s11255-024-04272-6. Online ahead of print. Int Urol Nephrol. 2024. PMID: 39546190 - Assessment of the Correlation Between Serum Phosphate Level and Muscle Strength as Measured by Handgrip Strength in Patients Treated With Hemodialysis.
Ben-Noach D, Levy D, Raz M, Anbar R, Schwartz D, Kliuk-Ben Bassat O. Ben-Noach D, et al. Can J Kidney Health Dis. 2024 Aug 6;11:20543581241267163. doi: 10.1177/20543581241267163. eCollection 2024. Can J Kidney Health Dis. 2024. PMID: 39114646 Free PMC article. - Machine learning progressive CKD risk prediction model is associated with CKD-mineral bone disorder.
Aoki J, Khalid O, Kaya C, Kothari T, Silberman M, Skordis C, Hughes J, Hussong J, Salama ME. Aoki J, et al. Bone Rep. 2024 Jul 4;22:101787. doi: 10.1016/j.bonr.2024.101787. eCollection 2024 Sep. Bone Rep. 2024. PMID: 39071944 Free PMC article. - Pruritus Severity and Serum Phosphate in CKD: A Post Hoc Analysis of Difelikefalin Studies.
Fishbane SN, Block GA, Evenepoel P, Budden J, Morin I, Menzaghi F, Wen W, Lerma EV. Fishbane SN, et al. Kidney360. 2024 Sep 1;5(9):1270-1280. doi: 10.34067/KID.0000000000000520. Epub 2024 Jul 22. Kidney360. 2024. PMID: 39037824 Free PMC article. - High Serum Phosphate Is Associated with Cardiovascular Mortality and Subclinical Coronary Atherosclerosis: Systematic Review and Meta-Analysis.
Torrijo-Belanche C, Moreno-Franco B, Muñoz-Cabrejas A, Calvo-Galiano N, Casasnovas JA, Sayón-Orea C, Guallar-Castillón P. Torrijo-Belanche C, et al. Nutrients. 2024 May 24;16(11):1599. doi: 10.3390/nu16111599. Nutrients. 2024. PMID: 38892532 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous